Cargando…

Recognition of early mortality in multiple myeloma by a prediction matrix

Early mortality (EM; death ≤ 6 months from diagnosis) has been reported in several newly diagnosed multiple myeloma (NDMM) trials. Before the era of novel agents, the incidence was 10%‐14%. Causes of death included infections/pneumonia, renal failure, refractory disease, and cardiac events. Staging...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terebelo, Howard, Srinivasan, Shankar, Narang, Mohit, Abonour, Rafat, Gasparetto, Cristina, Toomey, Kathleen, Hardin, James W., Larkins, Gail, Kitali, Amani, Rifkin, Robert M., Shah, Jatin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601204/ https://www.ncbi.nlm.nih.gov/pubmed/28543165 http://dx.doi.org/10.1002/ajh.24796

Ejemplares similares

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
por: Abonour, Rafat, et al.
Publicado: (2018)

Development of a prognostic model for overall survival in multiple myeloma using the Connect(®) MM Patient Registry
por: Terebelo, Howard R., et al.
Publicado: (2019)

Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect(®) MM Registry
por: Abonour, Rafat, et al.
Publicado: (2020)

Connect MM Registry as a national reference for United States multiple myeloma patients
por: Ailawadhi, Sikander, et al.
Publicado: (2019)

P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY
por: Abonour, Rafat, et al.
Publicado: (2023)

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect(®) MM Registry
por: Lee, Hans C., et al.
Publicado: (2021)

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis
por: Ailawadhi, Sikander, et al.
Publicado: (2020)

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry
por: Richter, Joshua, et al.
Publicado: (2022)

Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited
por: Yang, Jay, et al.
Publicado: (2012)

Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma
por: Liu, Enze, et al.
Publicado: (2023)

The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research
por: Flick, E Dawn, et al.
Publicado: (2023)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019)

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Cryopreservation Preserves Cell-Type Composition and Gene Expression Profiles in Bone Marrow Aspirates From Multiple Myeloma Patients
por: Chen, Duojiao, et al.
Publicado: (2021)

Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myeloma
por: Johnson, Travis S., et al.
Publicado: (2023)

Extramedullary Myeloid Leukemia in the Setting of a Myeloproliferative Neoplasm
por: Kosti, Jorgena, et al.
Publicado: (2022)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009)

The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl‐2 inhibitor (ABT‐199) displays synergistic anti‐myeloma effects in myeloma cells without a t(11;14) translocation
por: Sundaramoorthy, Pasupathi, et al.
Publicado: (2018)

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
por: Shah, Jatin J, et al.
Publicado: (2009)

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
por: Davies, Faith, et al.
Publicado: (2021)

P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) AFTER INITIAL BORTEZOMIB (V)-BASED INDUCTION VS PARENTERAL V-BASED THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
por: Rifkin, R. M., et al.
Publicado: (2022)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tuchman, S. A., et al.
Publicado: (2012)

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
por: Sudha, Parvathi, et al.
Publicado: (2022)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Multimodality Imaging Including PET/CT in a Patient with Amyloid Arthropathy and Multiple Myeloma
por: dos Reis Teixeira, Afrânio, et al.
Publicado: (2016)

Bone matrix to growth factors: location, location, location
por: Rifkin, Daniel B., et al.
Publicado: (2010)

Anaplastic Multiple Myeloma: Case Series and Literature Review
por: Wu, Jian, et al.
Publicado: (2022)

NIAAA’s College Alcohol Intervention Matrix: CollegeAIM
por: Cronce, Jessica M., et al.
Publicado: (2018)

Multiple myeloma presenting as bilateral orbital proptosis
por: Malik, Archana, et al.
Publicado: (2009)

Granulomatosis with Polyangiitis Presenting as Pyrexia of Unknown Origin, Leukocytosis, and Microangiopathic Haemolytic Anemia
por: Terebelo, Sima, et al.
Publicado: (2017)

Sotatercept in patients with osteolytic lesions of multiple myeloma
por: Abdulkadyrov, Kudrat M, et al.
Publicado: (2014)

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma
por: Zheng, Zhihong, et al.
Publicado: (2018)

A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting
por: Rifkin, Robert M., et al.
Publicado: (2019)

Matrix metalloproteinases and tissue inhibitors in multiple myeloma: promote or inhibit?
por: Li, Yan-Ying, et al.
Publicado: (2023)

The Breaking Point: Family Dementia Caregivers’ Recognition of the Need to Intervene
por: Harrington, Candace, et al.
Publicado: (2020)

Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression
por: Larkins, Teri L, et al.
Publicado: (2006)

Articulation constrained learning with application to speech emotion recognition
por: Shah, Mohit, et al.
Publicado: (2019)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma
por: Baz, Rachid C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p51n06j8bhk6f87uiahpagg4gf